Truist assumed coverage of Arcus Biosciences with a Buy rating and a price target of $35, up from $30. The firm views the setup as "increasingly compelling," with upside driven by casdatifan's validated mechanism of action and emerging best-in-class profile in clear cell renal cell carcinoma, the analyst tells investors.
